Workflow
Changyao Group(300391)
icon
Search documents
长药控股(300391) - 2014 Q4 - 年度财报
2015-04-16 16:00
Financial Performance - The company's operating revenue for 2014 was ¥243,428,659.11, a decrease of 4.68% compared to ¥255,385,121.46 in 2013[15] - Operating profit fell to ¥18,577,999.98 in 2014, down 43.00% from ¥32,595,009.37 in the previous year[15] - The net profit attributable to shareholders decreased by 17.85% to ¥28,718,706.93 from ¥34,958,543.50 in 2013[15] - The weighted average return on equity dropped to 10.65% in 2014 from 19.17% in 2013, a decline of 8.52 percentage points[15] - The company reported a basic earnings per share of ¥0.5043, down 27.87% from ¥0.6992 in the previous year[15] - The gross margin for turbochargers decreased by 8.37% to 34.69%, while the revenue from other products increased by 52.68%[41] Assets and Liabilities - The total assets increased by 21.13% to ¥681,847,082.99 at the end of 2014, compared to ¥562,919,130.56 at the end of 2013[15] - The company's total liabilities decreased by 13.21% to ¥317,140,295.17 in 2014 from ¥365,416,546.67 in 2013[15] - The asset-liability ratio improved to 46.51% in 2014, down from 64.91% in 2013, a reduction of 18.40 percentage points[15] - Cash and cash equivalents increased by 456.49% to ¥29,828,142.21, reflecting improved liquidity[35] - The company's total assets included cash of ¥90,517,090.95, which represented 13.28% of total assets, a decrease of 3.52% from the previous year[42] Cash Flow - The net cash flow from operating activities was negative at -¥38,880,883.48, a significant decrease of 279.52% compared to ¥21,658,761.26 in 2013[15] - Operating cash inflow for 2014 was ¥143,908,463.73, a 1.19% increase from 2013, while cash outflow rose by 51.63% to ¥182,789,347.21, resulting in a net cash flow of -¥38,880,883.48[34] - The net cash flow from financing activities increased by 123.86% to ¥101,042,098.06, primarily due to increased funds raised from stock issuance[36] Research and Development - Research and development expenses totaled 16.16 million yuan, accounting for 6.64% of total revenue, with eight projects ongoing[32] - The company aims to enhance product technology and process control capabilities to maintain its core technological advantages and high cost-performance ratio[51] Shareholder Information - The company distributed a cash dividend of RMB 1.30 per 10 shares, totaling RMB 8,667,100.00, which represents 30.18% of the net profit attributable to shareholders[58] - The total distributable profit available for shareholders as of December 31, 2014, was RMB 106,287,175.93, with a net profit of RMB 30,920,132.54 for the year[55] Corporate Governance - The company has established a management system for insider information to ensure compliance with disclosure regulations[58] - The company maintains independent business operations and has a complete operational system, ensuring no financial guarantees or non-operational fund occupation by the controlling shareholder during the reporting period[128] - The board of directors and supervisory board are elected according to legal procedures, ensuring compliance with laws and regulations, and all members actively participate in training to enhance governance[129][130] Employee Information - The company employed a total of 750 staff, with 58% in production and auxiliary roles, 21% in administrative management, and 14% in technical positions[123] - As of December 31, 2014, the company had 117 disabled employees, representing 28.4% of the total workforce[124] Audit and Compliance - The audit opinion for the financial statements is unqualified, indicating that the financial statements fairly reflect the company's financial position and operating results for the year ended December 31, 2014[148] - The financial statements are prepared in Renminbi (RMB), with the unit specified as yuan[150] Market and Industry Risks - The company faced risks related to industry policies and macroeconomic fluctuations, which could impact demand for internal combustion engines[21] - The company is undergoing a transition in emission standards from National III to National IV, which may slow down product sales growth[21]
长药控股(300391) - 2015 Q1 - 季度财报
2015-04-16 16:00
Financial Performance - Total revenue for Q1 2015 was ¥58,465,584.36, a slight increase of 0.26% compared to ¥58,312,246.52 in the same period last year[7] - Net profit attributable to ordinary shareholders decreased by 47.81% to ¥2,797,044.43 from ¥5,359,676.44 year-on-year[7] - Basic earnings per share dropped by 60.82% to ¥0.0420 from ¥0.1072 in the same period last year[7] - Total profit for the period was 2.59 million RMB, a decrease of 44.48% compared to the same period last year[18] - Net profit for the period was 2.80 million RMB, down 47.81% year-on-year[18] - The weighted average return on net assets fell to 0.76% from 5.28% year-on-year, reflecting declining profitability[7] - Total operating revenue for Q1 2015 was CNY 58,465,584.36, a slight increase of 0.26% compared to CNY 58,312,246.52 in the previous period[61] - Net profit for Q1 2015 was CNY 2,797,044.43, a decrease of 47.9% compared to CNY 5,359,676.44 in the same period last year[62] - The company reported a total comprehensive income of CNY 2,797,044.43, down from CNY 5,359,676.44 in the previous period[63] Cash Flow and Assets - Operating cash flow for the quarter was negative at -¥22,308,800.86, an improvement of 9.48% from -¥24,644,618.77 in the previous year[7] - The net cash flow from operating activities was -22,308,800.86, an improvement from -24,644,618.77 in the previous period[70] - Total cash inflow from operating activities was 23,216,360.96, down from 31,146,660.37 in the previous period[70] - Cash outflow from operating activities totaled 45,525,161.82, compared to 55,791,279.14 in the previous period[70] - The ending cash and cash equivalents balance was 99,666,388.75, significantly up from 19,971,502.14 in the previous period[71] - Cash inflow from financing activities was 163,800,000.00, up from 119,322,924.54 in the previous period[71] - The company’s cash and cash equivalents increased by 36,652,611.61 compared to a decrease of 13,214,132.79 in the previous period[71] - Total assets increased by 7.39% to ¥732,217,050.33 from ¥681,847,082.99 at the end of the previous year[7] - Current assets rose to CNY 407,458,753.08, compared to CNY 366,400,756.57 at the start of the quarter, reflecting a growth of about 11.1%[53] - Cash and cash equivalents increased to CNY 103,050,643.58 from CNY 90,517,090.95, marking a rise of approximately 13.5%[53] Liabilities and Equity - Total liabilities decreased to CNY 364,713,218.08 from CNY 317,140,295.17, a reduction of about 15%[55] - The company's equity attributable to shareholders rose to CNY 367,503,832.25, compared to CNY 364,706,787.82 at the beginning of the quarter, reflecting a modest increase of about 0.8%[56] - Short-term borrowings decreased to CNY 165,500,000.00 from CNY 206,009,315.71, a decline of approximately 19.6%[54] - The company reported a decrease in accounts payable to CNY 75,475,054.19 from CNY 54,953,303.68, indicating a rise of about 37.3%[54] Market and Strategic Initiatives - The company plans to enhance market competitiveness by expanding customer outreach and investing in new markets[19] - The company faces risks from weak downstream demand and intensified market competition, particularly in the commercial vehicle and engineering machinery sectors[19] - 康跃科技在2015年第一季度的业绩总结中,报告了总收入为5000万元,同比增长15%[28] - 用户数据方面,活跃用户数达到了200万,同比增长20%[29] - 对于未来展望,康跃科技预计2015年全年收入将达到2亿元,增长率为25%[30] - 新产品研发方面,康跃科技计划在2015年推出三款新产品,预计将占总收入的30%[28] - 市场扩张策略包括进入东南亚市场,预计在未来两年内将增加10%的市场份额[29] - 并购方面,公司正在考虑收购一家小型科技公司,以增强其技术能力和市场竞争力[33] Risks and Challenges - The company faces risks related to industry policy changes, debt repayment, and high accounts receivable[10] - The company has not experienced significant changes in its annual operational plan during the reporting period[19] - The company has implemented a sales collection assessment mechanism to manage accounts receivable effectively[20] - Inventory at the end of the reporting period was ¥56,171,700, representing 13.8% of current assets, which may affect liquidity[11] - The company is enhancing production cost control and optimizing product structure to ensure reasonable inventory levels[21]
长药控股(300391) - 2014 Q3 - 季度财报
2014-10-21 16:00
康跃科技股份有限公司 2014 年第三季度报告 2014-019 2014 年 10 月 1 康跃科技股份有限公司 2014 年第三季度报告全文 康跃科技股份有限公司 2014 年第三季度报告全文 康跃科技股份有限公司 2014 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 第一节 重要提示 本公司董事会、监事会及其董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误 导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人郭锡禄、主管会计工作负责人郑树峰及会计机构负责人(会计主管人员)王德兴声明:保证 季度报告中财务报告的真实、完整。 2 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产(元) | 708,561,578.52 | | 562,919,130.56 | 25.87% | | ...